Alterity Therapeutics News

Alterity Therapeutics Analyst Ratings

BenzingaMar 7 08:40 ET

Ladenburg Thalmann Maintains Buy on Alterity Therapeutics, Lowers Price Target to $10

BenzingaJun 5, 2023 06:55 ET

Ladenburg Thalmann Initiates Alterity Therapeutics at Buy With $2 Price Target

MT NewswiresAug 3, 2022 09:34 ET

Alterity Therapeutics Initiated at Buy by Ladenburg Thalmann

Dow JonesAug 3, 2022 07:17 ET

Alterity Therapeutics Price Target Announced at $2.00/Share by Ladenburg Thalmann

Dow JonesAug 3, 2022 07:17 ET

Alterity Therapeutics analyst ratings

Benzinga Analyst RatingsAug 3, 2022 07:12 ET

Ladenburg Thalmann Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $2

Benzinga Real-time NewsAug 3, 2022 07:10 ET

Goldman Sachs Adjusts Alterity Therapeutics' Price Target to $3 from $11, Keeps Neutral Rating

MT NewswiresJun 23, 2022 13:02 ET

Alterity Therapeutics Price Target Cut to $3.00/Share From $11.00 by Goldman Sachs

Dow JonesJun 23, 2022 07:27 ET

Alterity Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow JonesJun 23, 2022 07:27 ET

Alterity Therapeutics analyst ratings

Benzinga Analyst RatingsJun 23, 2022 07:18 ET

Goldman Sachs Maintains Neutral on Alterity Therapeutics, Lowers Price Target to $3

Benzinga Real-time NewsJun 23, 2022 07:18 ET